Linical Evolution News Today

Response Pharmaceuticals, Inc., has unveiled significant findings from its Phase 1b clinical trial of RDX-002, signaling a potential breakthrough in combatting antipsychotic-induced weight gain (AIWG).

Response Pharmaceuticals, Inc., has unveiled significant findings from its Phase 1b clinical trial of RDX-002, signaling a potential breakthrough in combatting antipsychotic-induced weight gain (AIWG).

Last month, OSP was excited to write about One2Treat, a progressive startup specializing in digital health solutions, which has launched a forward-thinking approach aimed at tackling key challenges in the biopharma industry.

To make testing for colorectal cancer more bearable than biannunal colonoscopies, a test has been designed that is simple, effective, non-invasive and not unpleasant.

The European Commission has granted Orphan Medicinal Product designation for zatolmilast an investigational treatment for Fragile X syndrome (FXS), a leading cause of inherited intellectual disability and autism.

In a groundbreaking revelation, a study conducted by RCSI University of Medicine and Health Sciences and Children’s Health Ireland has confirmed the safety and efficacy of a Cystic Fibrosis drug in newborns as young as four weeks old.

In a landmark development poised to reshape the landscape of medical diagnostics, the U.S. Food and Drug Administration (FDA) has officially sanctioned Prenosis' pioneering artificial intelligence (AI) tool designed for the early detection of sepsis.

Life sciences investment firm Medicxi has injected $40 million in D3 Bio, a biotechnology company based in Shanghai, China.

Life sciences investment firm Medicxi has injected $40 million in D3 Bio, a biotechnology company based in Shanghai, China.

Precision oncology innovator SimBioSys and General Inception have joined forces in a strategic partnership aimed at revolutionizing cancer drug development.